SG11201907032RA - Amino pyrimidine compounds useful as ssao inhibitors - Google Patents
Amino pyrimidine compounds useful as ssao inhibitorsInfo
- Publication number
- SG11201907032RA SG11201907032RA SG11201907032RA SG11201907032RA SG11201907032RA SG 11201907032R A SG11201907032R A SG 11201907032RA SG 11201907032R A SG11201907032R A SG 11201907032RA SG 11201907032R A SG11201907032R A SG 11201907032RA SG 11201907032R A SG11201907032R A SG 11201907032RA
- Authority
- SG
- Singapore
- Prior art keywords
- indiana
- indianapolis
- box
- international
- pct
- Prior art date
Links
- 150000005005 aminopyrimidines Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102100027159 Membrane primary amine oxidase Human genes 0.000 abstract 1
- 101710132836 Membrane primary amine oxidase Proteins 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 August 2018 (23.08.2018) WIP0 I PCT omit IIl °nolo onm iflo oimIE (10) International Publication Number WO 2018/151985 Al (51) International Patent Classification: A61K 31/506 (2006.01) A61P 1/16 (2006.01) CO7D 239/47 (2006.01) (21) International Application Number: PCT/US2018/017152 (22) International Filing Date: 07 February 2018 (07.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/CN2017/000157 14 February 2017 (14.02.2017) CN PCT/CN2017/117791 21 December 2017 (21.12.2017) CN (71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US). (71) Applicant (for MG only): LILLY CHINA RESEARCH AND DEVELOPMENT CO., LTD [CN/CN]; 780 Cailun Road, Rm. 819, Zhangjiang High Technology Park, Pudong New Area, Shanghai 20000 (CN). (72) Inventors: FAN, Mengyang; c/o Eli Lilly And Compa- ny, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). QIN, Luoheng; c/o Eli Lilly And Company, P.O. Box 6288, Indianaoplis, Indiana 46206-6288 (US). WEI, Yi; c/ o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). ZHOU, Guoqiang; c/o Eli Lil- ly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). ZHOU, Jingye; c/o Eli Lilly And Com- pany, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). (74) Agent: MYERS, James B. et al.; ELI LILLY AND COM- PANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) In (54) Title: AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS 00 1-1 NH 2 1-1 (57) : The present invention provides compounds of the formula below, pharmaceutically acceptable salts of the compounds, methods of treating patients for liver disease, and processes for preparing the compounds.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/000157 WO2018148856A1 (en) | 2017-02-14 | 2017-02-14 | Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors |
| PCT/CN2017/117791 WO2018149226A1 (en) | 2017-02-14 | 2017-12-21 | Amino pyrimidine compounds useful as ssao inhibitors |
| PCT/US2018/017152 WO2018151985A1 (en) | 2017-02-14 | 2018-02-07 | Amino pyrimidine compounds useful as ssao inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907032RA true SG11201907032RA (en) | 2019-08-27 |
Family
ID=63169081
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907032RA SG11201907032RA (en) | 2017-02-14 | 2018-02-07 | Amino pyrimidine compounds useful as ssao inhibitors |
| SG10201913492YA SG10201913492YA (en) | 2017-02-14 | 2018-02-07 | Amino pyrimidine compounds useful as ssao inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913492YA SG10201913492YA (en) | 2017-02-14 | 2018-02-07 | Amino pyrimidine compounds useful as ssao inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10278970B2 (en) |
| EP (1) | EP3582780B1 (en) |
| JP (2) | JP7030827B2 (en) |
| KR (1) | KR20190117007A (en) |
| CN (2) | CN108778278B (en) |
| AU (1) | AU2018221322B2 (en) |
| CA (1) | CA3052044A1 (en) |
| DK (1) | DK3582780T3 (en) |
| ES (1) | ES2897666T3 (en) |
| IL (1) | IL268625A (en) |
| MX (1) | MX2019009501A (en) |
| SG (2) | SG11201907032RA (en) |
| WO (3) | WO2018148856A1 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018027892A1 (en) | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Amino pyrimidine ssao inhibitors |
| WO2018148856A1 (en) | 2017-02-14 | 2018-08-23 | Eli Lilly And Company | Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors |
| CN109251166B (en) * | 2017-07-13 | 2021-11-05 | 广东东阳光药业有限公司 | Amine compounds inhibiting SSAO/VAP-1 and their application in medicine |
| CN109810041B (en) * | 2017-11-21 | 2023-08-15 | 药捷安康(南京)科技股份有限公司 | Halogenated allylamine SSAO/VAP-1 inhibitors and their applications |
| CN109988106B (en) * | 2017-12-29 | 2023-03-31 | 广东东阳光药业有限公司 | Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine |
| WO2020006177A1 (en) * | 2018-06-29 | 2020-01-02 | Blade Therapeutics, Inc. | Vascular adhesion protein-1 (vap-1) modulators and therapeutic uses thereof |
| CN110938059A (en) * | 2018-09-25 | 2020-03-31 | 上海轶诺药业有限公司 | Preparation and application of aminourea sensitive amine oxidase inhibitor |
| WO2020063854A1 (en) * | 2018-09-27 | 2020-04-02 | 南京明德新药研发有限公司 | Quinoline-based derivatives as vap-1 inhibitors |
| PE20211467A1 (en) | 2018-10-29 | 2021-08-05 | Boehringer Ingelheim Int | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES OF THEM |
| WO2020089025A1 (en) | 2018-10-29 | 2020-05-07 | Boehringer Ingelheim International Gmbh | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
| CN111434662B (en) * | 2019-01-11 | 2023-01-10 | 药捷安康(南京)科技股份有限公司 | Haloallylamine compound and application thereof |
| CN111471037B (en) * | 2019-01-23 | 2023-02-10 | 药捷安康(南京)科技股份有限公司 | Allylamine compounds and their applications |
| CA3155114A1 (en) | 2019-10-29 | 2021-05-06 | Eccogene (Shanghai) Co., Ltd. | Semicarbazide-sensitive amino oxidase inhibitors and use thereof |
| CN113149957A (en) * | 2020-01-23 | 2021-07-23 | 轶诺(浙江)药业有限公司 | Preparation and application of aminourea sensitive amine oxidase inhibitor |
| EP4204405A4 (en) * | 2020-08-25 | 2024-05-29 | Eli Lilly and Company | Polymorphs of an ssao inhibitor |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008123469A1 (en) | 2007-03-30 | 2008-10-16 | Japan Tobacco Inc. | Six-membered amide compound and use thereof |
| CA2693290A1 (en) | 2007-07-20 | 2009-01-29 | Merck Frosst Canada Ltd. | Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| NZ585528A (en) * | 2007-11-21 | 2012-08-31 | Pharmaxis Ltd | Haloallylamine inhibitors of ssao/vap-1 and uses therefor |
| ES2651690T3 (en) * | 2009-09-16 | 2018-01-29 | Astellas Pharma Inc. | Glycine compound |
| JP2011136942A (en) | 2009-12-28 | 2011-07-14 | Kowa Co | Novel substituted pyrimidine derivative and medicine comprising the same |
| HUE028394T2 (en) | 2011-03-15 | 2016-12-28 | Astellas Pharma Inc | Guanidin Compound |
| EP2844637B1 (en) | 2012-05-02 | 2018-03-28 | Boehringer Ingelheim International GmbH | Substituted 3-haloallylamine inhibitors of ssao and uses thereof |
| SG11201503559TA (en) | 2012-11-16 | 2015-06-29 | Bristol Myers Squibb Co | Pyrrolidine gpr40 modulators |
| US8962641B2 (en) * | 2013-04-17 | 2015-02-24 | Boehringer Ingelheim International Gmbh | Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof |
| WO2014184104A1 (en) | 2013-05-17 | 2014-11-20 | Boehringer Ingelheim International Gmbh | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof |
| GB201416444D0 (en) * | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New compounds |
| WO2018027892A1 (en) | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Amino pyrimidine ssao inhibitors |
| WO2018148856A1 (en) | 2017-02-14 | 2018-08-23 | Eli Lilly And Company | Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors |
-
2017
- 2017-02-14 WO PCT/CN2017/000157 patent/WO2018148856A1/en not_active Ceased
- 2017-12-21 WO PCT/CN2017/117791 patent/WO2018149226A1/en not_active Ceased
-
2018
- 2018-02-07 EP EP18706109.8A patent/EP3582780B1/en active Active
- 2018-02-07 MX MX2019009501A patent/MX2019009501A/en unknown
- 2018-02-07 SG SG11201907032RA patent/SG11201907032RA/en unknown
- 2018-02-07 CN CN201880000825.XA patent/CN108778278B/en active Active
- 2018-02-07 SG SG10201913492YA patent/SG10201913492YA/en unknown
- 2018-02-07 CA CA3052044A patent/CA3052044A1/en active Pending
- 2018-02-07 WO PCT/US2018/017152 patent/WO2018151985A1/en not_active Ceased
- 2018-02-07 AU AU2018221322A patent/AU2018221322B2/en active Active
- 2018-02-07 ES ES18706109T patent/ES2897666T3/en active Active
- 2018-02-07 JP JP2019543810A patent/JP7030827B2/en active Active
- 2018-02-07 DK DK18706109.8T patent/DK3582780T3/en active
- 2018-02-07 CN CN202210027271.0A patent/CN114369095B/en active Active
- 2018-02-07 KR KR1020197026490A patent/KR20190117007A/en not_active Ceased
- 2018-06-19 US US16/012,140 patent/US10278970B2/en active Active
-
2019
- 2019-03-18 US US16/356,895 patent/US10471060B2/en active Active
- 2019-08-11 IL IL26862519A patent/IL268625A/en unknown
-
2022
- 2022-02-22 JP JP2022025774A patent/JP7247389B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201913492YA (en) | 2020-03-30 |
| AU2018221322A1 (en) | 2019-08-15 |
| DK3582780T3 (en) | 2021-11-01 |
| WO2018148856A1 (en) | 2018-08-23 |
| EP3582780A1 (en) | 2019-12-25 |
| IL268625A (en) | 2019-10-31 |
| JP2022068325A (en) | 2022-05-09 |
| US20180296560A1 (en) | 2018-10-18 |
| MX2019009501A (en) | 2019-11-05 |
| US20190275041A1 (en) | 2019-09-12 |
| US10278970B2 (en) | 2019-05-07 |
| EP3582780B1 (en) | 2021-10-13 |
| CN114369095A (en) | 2022-04-19 |
| CN108778278A (en) | 2018-11-09 |
| CN108778278B (en) | 2022-01-28 |
| CN114369095B (en) | 2025-03-14 |
| AU2018221322B2 (en) | 2022-04-14 |
| WO2018151985A1 (en) | 2018-08-23 |
| KR20190117007A (en) | 2019-10-15 |
| WO2018149226A1 (en) | 2018-08-23 |
| JP7030827B2 (en) | 2022-03-07 |
| JP7247389B2 (en) | 2023-03-28 |
| CA3052044A1 (en) | 2018-08-23 |
| ES2897666T3 (en) | 2022-03-02 |
| US10471060B2 (en) | 2019-11-12 |
| JP2020507589A (en) | 2020-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201907846VA (en) | Therapeutic rna | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201901457TA (en) | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment | |
| SG11201906163TA (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same |